LEADER 02919nam  2200637Ia 450 
001 9910819198103321
005 20240516204016.0
010   $a0-19-173987-1
010   $a0-19-960699-4
010   $a1-283-58075-6
010   $a9786613893208
010   $a0-19-157517-8
035   $a(CKB)2430000000022719
035   $a(EBL)975599
035   $a(OCoLC)801363649
035   $a(SSID)ssj0000352951
035   $a(PQKBManifestationID)11270462
035   $a(PQKBTitleCode)TC0000352951
035   $a(PQKBWorkID)10286032
035   $a(PQKB)10068149
035   $a(MiAaPQ)EBC975599
035   $a(StDuBDS)EDZ0000091504
035   $a(Au-PeEL)EBL975599
035   $a(CaPaEBR)ebr10581391
035   $a(CaONFJC)MIL389320
035   $a(EXLCZ)992430000000022719
100   $a20070920d2007      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aEndocrine therapies in breast cancer /$fedited by Aman U. Buzdar
205   $a1st ed.
210   $aOxford ;$aNew York $cOxford University Press$d2007
215   $a1 online resource (129 p.)
225 1 $aOxford oncology library
300   $aDescription based upon print version of record.
311   $a0-19-921814-5 
320   $aIncludes bibliographical references and index.
327   $aContents; Contributors; 1 Selection of patients for endocrine therapies; 2 Ovarian ablation; 3 Antioestrogens; 4 Aromatase inhibitors in early and advanced disease; 5 Fulvestrant in metastatic disease; 6 Progestins and androgens; 7 Combined endocrine and chemotherapy in breast cancer; 8 Hormone replacement therapy in patients with a prior history of breast cancer; 9 Chemoprevention; Index; A; B; C; D; E; F; G; H; I; L; M; N; O; P; R; S; T; V; W; Z
330   $aBreast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able toreduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging 
410  0$aOxford oncology library.
606   $aBreast$xCancer$xHormone therapy
606   $aBreast$xCancer$xEndocrine aspects
615  0$aBreast$xCancer$xHormone therapy.
615  0$aBreast$xCancer$xEndocrine aspects.
676   $a616.99/449071
701   $aBuzdar$b Aman U$01656483
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910819198103321
996   $aEndocrine therapies in breast cancer$94009403
997   $aUNINA